Date: 2015-01-07
Type of information: Nomination
Compound:
Company: BioMarin Pharmaceutical (USA - CA)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 7, 2015, BioMarin Pharmaceutical announced that, after a tenure of more than a decade, Pierre Lapalme has elected to step down as Chairman of the Company\'s Board of Directors following the annual meeting of stockholders anticipated in June of this year. Mr. Lapalme will seek re-election to serve as a Director on BioMarin\'s Board at the meeting. Mr. Lapalme joined BioMarin\'s Board of Directors in January 2004 and was named as Chairman of the Board in August 2004. Following Mr. Lapalme\'s decision, the Board elected to revise the organizational structure of the Board and the Company. The Board created the position of Lead Independent Director to serve as a liaison between the Chief Executive Officer and the independent directors, and to facilitate discussions and deliberation among the independent directors in fulfilling their oversight responsibilities for the Company. The Board has determined that Richard Meier will serve as the Lead Independent Director effective on Mr. Lapalme stepping down as Chairman. Mr. Meier joined the Board in December 2006. Also effective on Mr. Lapalme stepping down as Chairman, to better align the operational leadership of the Company, the Board has determined Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will assume the role of Chairman of the Board. Mr. Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors. All of the planned changes are contingent on the reelection of Messrs. Lapalme, Meier and Bienaimé to the Board of Directors at the annual meeting of stockholders later this year.
Financial terms:
Latest news:
